Market Overview:
Global Mice Model Market size and share is currently valued at USD 1.36 billion in 2023 and is anticipated to generate an estimated revenue of USD 2.68 billion by 2032, according to the latest study by Polaris Market Research. Besides, the report notes that the market exhibits a robust 7.8% Compound Annual Growth Rate (CAGR) over the forecasted timeframe, 2024 – 2032
The mice model market has witnessed steady growth over the past decade, driven by increasing regulatory requirements for drug efficacy and safety assessment, as well as technological innovations in genetically engineered mice. As a result, both public and private institutions are leveraging sophisticated mouse models to simulate complex human disease mechanisms and gain insights into potential clinical outcomes.
The expanding use of humanized mice in biomedical research has also strengthened the market. These models, which carry human genes or cells, provide more accurate representations of disease progression in humans, especially for studies related to cancer, autoimmune disorders, and infectious diseases.
Moreover, the global rise in chronic and lifestyle-related diseases has accelerated the need for robust animal models to develop novel therapies. As pharmaceutical pipelines continue to grow and new biopharmaceuticals emerge, mice remain central to preclinical validation.
Growth Drivers
Several factors are propelling the mice model market forward:
- Rising Preclinical Research Activity: A growing number of pharmaceutical companies are focusing on early-stage drug discovery, increasing the demand for reliable preclinical testing methods involving mice models.
- Advancements in Genetic Engineering: CRISPR/Cas9 and other gene-editing technologies have made it easier to create genetically engineered mice with precise disease phenotypes. This enables researchers to model human conditions with greater accuracy.
- Expansion of Personalized Medicine: The shift toward individualized treatment approaches requires in-depth study of genetic mutations and therapeutic responses. Mice models serve as essential platforms to test these tailored interventions.
- Increase in Cancer Research: Oncology research continues to be one of the largest application areas for mice models. Patient-derived xenografts (PDX) and immunodeficient mice are particularly useful for studying tumor biology and evaluating new anticancer drugs.
- Academic and Government Support: Numerous government-funded initiatives and university-led projects are utilizing mouse models for fundamental and translational research, further fueling market growth.
Key Companies:
The competitive landscape of the mice model market is marked by innovation, strategic partnerships, and service expansions. Key players are focusing on enhancing their model portfolios, developing custom solutions, and investing in advanced gene-editing platforms.
Prominent companies operating in the mice model market include:
- Charles River Laboratories International, Inc.
- Cyagen Biosciences Inc.
- Envigo
- genOway S.A.
- Harbour Biomed
- Hera Biolabs
- Inotiv
- Janvier Labs
- Ozgene Pty Ltd.
- PolyGene
- Sage Labs
- Taconic Biosciences, Inc.
- The Jackson Laboratory
These companies are actively collaborating with research institutions and pharmaceutical companies to expand access to high-quality mouse models and accelerate translational discoveries.
𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞:
https://www.polarismarketresearch.com/industry-analysis/mice-model-market
Market Segmentation:
Mice Model Market, Model and Service Outlook (Revenue – USD Billion, 2019-2032)
- Municipal Solid Waste
- Process Waste
- Agriculture Waste
- Others
Mice Model Market, Application Outlook (Revenue – USD Billion, 2019-2032)
- Neurology
- Oncology
- Cardiovascular Diseases
- Genetic Diseases
- Others
Mice Model Market, End User Outlook (Revenue – USD Billion, 2019-2032)
- Contract Research and Manufacturing Organizations
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutes
- Others
Regional Analysis
North America dominates the mice model market, with the United States at the forefront owing to its robust biomedical research infrastructure, significant funding from the National Institutes of Health (NIH), and presence of leading pharmaceutical firms. The region benefits from a well-established regulatory framework supporting preclinical research.
Europe is also a major market, driven by strong academic research networks and growing biotech activity, especially in countries like Germany, the UK, and France. The region’s focus on ethical animal use and welfare has also spurred investment in genetically defined models that reduce the number of animals needed per study.
Asia-Pacific is expected to witness the fastest growth over the forecast period. Countries such as China, Japan, and India are rapidly expanding their biomedical research capabilities, supported by government initiatives and a growing number of clinical trials. Cost-effectiveness and skilled research talent make the region attractive for outsourcing research using animal models.
Latin America and the Middle East & Africa represent emerging markets, with increasing collaboration between local institutions and global research organizations contributing to market development.
Conclusion:
As biomedical research becomes more sophisticated and targeted, the global mice model market is set to grow at a steady pace. Driven by increasing demand for in vivo studies, technological innovation, and expansion of personalized medicine, mice models will continue to play a foundational role in shaping the future of drug development and disease understanding.
More Trending Latest Reports By Polaris Market Research:
Durable Medical Equipment Market
Revolutionizing Healthcare: The Power of Patient Handling Equipment Market